Evolve Biologics, Therapure Biopharma’s Biologics Division, Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

MISSISSAUGA, Ontario--()--Evolve Biologics, the biologics division of Therapure Biopharma Inc., today announced that in February 2018 the company confidentially submitted a draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common shares. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.

Contacts

Gagnier Communications
Jeffrey Mathews / Dan Gagnier
646-569-5711

Recent Stories

RSS feed for Evolve Biologics

Release Summary

Evolve Biologics, Therapure Biopharma’s Biologics Division, 
Announces Confidential Submission of Draft Registration Statement for Proposed IPO

Evolve Biologics